Potent Coronavirus Anti-Viral Found

erek

erek

[H]F Junkie
Joined
Dec 19, 2005
Messages
10,875
STI-1499, A Potent Anti-SARS-CoV-2 Antibody, Demonstrates Ability To Completely Inhibit In Vitro Virus Infection In Preclinical Studies


"This press release and any statements made for and during any presentation or meeting contain forward-looking statements related to Sorrento Therapeutics, Inc., under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995 and subject to risks and uncertainties that could cause actual results to differ materially from those projected. Forward-looking statements include statements regarding the potency and potential blocking capabilities of STI-1499 and the impact on SARS-CoV-2, the SARS-CoV-2 Spike protein and viral entry; the expected length of any antiviral protection provided by STI-1499; the potential administration and applications of STI-1499; the potential for STI-1499 to protect against future mutations of coronavirus; the preclinical testing of STI-1499; the safety and efficacy of STI-1499; the readiness of Sorrento's cGMP facilities for large-scale production of STI-1499 for commercialization and Sorrento's expected capacity to produce drug substance; the expected time needed for Sorrento's cGMP facilities to produce doses of STI-1499; the potential inclusion of STI-1499 in the antibody cocktail (COVI-SHIELD™) that Sorrento is developing and its development as a stand-alone therapy; the therapeutic potential of STI-1499 for SARS-CoV-2 and COVID-19 disease and any potential ability to save lives; and Sorrento's potential position in the antiviral industry. Risks and uncertainties that could cause our actual results to differ materially and adversely from those expressed in our forward-looking statements, include, but are not limited to: risks related to Sorrento's and its subsidiaries', affiliates' and partners' technologies and prospects and collaborations with partners, including, but not limited to risks related to conducting pre-clinical studies and seeking IND regulatory approval for STI-1499; conducting and receiving results of clinical trials for STI-1499; the clinical and commercial success of STI-1499 against preventing and treating SARS-CoV-2 virus infections; the viability and success of STI-1499 in anti-viral therapeutic areas, including coronaviruses; clinical development risks, including risks in the progress, timing, cost, and results of clinical trials and product development programs; risk of difficulties or delays in obtaining regulatory approvals; risks that clinical study results may not meet any or all endpoints of a clinical study and that any data generated from such studies may not support a regulatory submission or approval; risks of manufacturing and supplying drug product; risks related to leveraging the expertise of its employees, subsidiaries, affiliates and partners to assist the company in the execution of its COVID-19 therapeutic product candidates strategies; risks related to Sorrento's debt obligations; risks related to the global impact of COVID-19; and other risks that are described in Sorrento's most recent periodic reports filed with the Securities and Exchange Commission, including Sorrento's Annual Report on Form 10-K for the year ended December 31, 2019, and subsequent Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission, including the risk factors set forth in those filings. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release and we undertake no obligation to update any forward-looking statement in this press release except as required by law."

https://investors.sorrentotherapeut...anti-sars-cov-2-antibody-demonstrates-ability
 
From the article:
Sorrento's commitment to life-enhancing therapies for patients is also demonstrated by our effort to advance a first-in-class (TRPV1 agonist) non-opioid pain management small molecule, resiniferatoxin ("RTX"), and ZTlido® (lidocaine topical system) 1.8% for the treatment of post-herpetic neuralgia. RTX is completing a phase IB trial for intractable pain associated with cancer and a phase 1B trial in osteoarthritis patients. ZTlido® was approved by the FDA on February 28, 2018.
Click to expand...


From this Reddit thread from April 4, 2018:
In Sorrento's most recent earnings call just last month, the firm gave disappointing news which caused the stock to lose a massive amount of value in the days that would follow the call.

1. They would not be marketing and selling their lead pain product, Ztildo, and would instead seek a divestment or partnership for the product.

This news completely dismantled my investment thesis. A divestment in this crowded pain management field is a difficult, if not impossible feat. The arrival of this news would also dismantle the thesis that their pain management portfolio would subsidize the development of their oncology pipeline.

How could this have been avoided?

I'm disappointed that I missed a few red flags that would have ultimately led me to the conclusion that they would not be commercializing this product. In the months leading up to, and following, the submission of an NDA and subsequent approval of a drug, a firm must build out a sales force of 50 - 100 employees, alongside increased marketing spending. Looking back at 10Q documents, it would have been fairly obvious that the firm had neither the capital, nor infrastructure, to fund such an endeavor.
Click to expand...


Going to be taking this "cure" with a massive grain of salt.
I sincerely hope it is true, but...

clockdogg said:
That's most important criteria for any new drug.
Click to expand...
...I really think this post sums it up.💰🤑 💹
 
Red Falcon said:
From the article:



From this Reddit thread from April 4, 2018:



Going to be taking this "cure" with a massive grain of salt.
I sincerely hope it is true, but...


...I really think this post sums it up.💰🤑 💹
Click to expand...

I agree with you, but I am hopeful.

It wouldn't be the first time a drug developed for something had disappointing results, but wound up being effective for something else.

Viagra for instance, was originally developed for cardiovascular disease, for which it was ultimately ineffective, but during testing they found a surprising and "upliflting" side effect.

The practice of using a drug for something completely different than it was originally intended is called "Drug Repositioning", and there are quite a few good successful examples of real and positive treatments coming from this practice.

So, while I agree, I am skeptical, because this sounds a little bit like a hail mary pass by a down and out pharmaceutical company, you never know.
 
Zarathustra[H] said:
I agree with you, but I am hopeful.

It wouldn't be the first time a drug developed for something had disappointing results, but wound up being effective for something else.

Viagra for instance, was originally developed for cardiovascular disease, for which it was ultimately ineffective, but during testing they found a surprising and "upliflting" side effect.

The practice of using a drug for something completely different than it was originally intended is called "Drug Repositioning", and there are quite a few good successful examples of real and positive treatments coming from this practice.

So, while I agree, I am skeptical, because this sounds a little bit like a hail mary pass by a down and out pharmaceutical company, you never know.
Click to expand...
Wow, I wasn't aware of that - learn something new everyday! (y)
Hmmm, maybe the dark cyberpunk future has a silver lining - while STI-1499 may or may not work for COVID-19, perhaps it will give everyone a nice stat-boost by 2077. :borg: ;)
 
  • Like
Reactions: erek
like this
PUUUUUUUUUUUMP AND DUUUUUUUUUUUUUUUUMP

tenor.gif
 
Literally. The Fox News article I read made it sound like it was ready for human trials. Further digging revealed it was only tested in a lab environment, they need animal testing before going to human trials in mid-July.
 
Another entry method has been identified recently that makes only focusing on spike protein non-foolproof. Good luck with that stock lol.
 
ZTLido was a crap product with a higher price and no advantages over generic Lidoderm patches. I'd be wary of any company that had ZTLido as a "lead" drug.

BTW, sildenafil (ingredient in Viagra) is effective and used for treating pulmonary hypertension. There was just a lot more money in marketing it for ED.
 
I think we've all seen plenty of in vitro tests that don't pan out in real world, human use. There are other issues here as well. However, even more importantly given this pandemic...

Nobody should be patenting a goddamn thing. Nobody should expect stocks to rise, nobody should be trying to get rich quick,pushing for their version to be deemed the preferred treatment/vaccine, etc. All research should be public domain, open, and collaborative. This doesn't mean we can't compensate private companies who help in the research, testing, and manufacture but we can do that without treating this like a typical profit-seeking endeavorl. There shouldn't be anything even slightly encouraging people to look for a proprietary solution and lock it down for payout, as we're seeing now.

Relying on the market in the face of this pandemic is part of the reason that the US has done so poorly at every level, from accessible testing to supplying health care workers properly. Profiteers costing lives is nothing new, but its time we put an end to this.
 
You must log in or register to reply here.
Back
Top